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ABSTRACT
Objectives This paper aims to estimate the percentage 
of European men who have sex with men (MSM) who 
may benefit from pre- exposure prophylaxis (PrEP), 
applying the three most widely used HIV risk indices for 
MSM (MSM Risk Index, Menza score, San Diego Early 
Test (SDET) score) and drawing on a large- scale multisite 
bio- behavioural survey (Sialon II).
Methods The Sialon II study was a bio- behavioural 
survey among MSM implemented in 13 European cities 
using either time- location sampling or respondent- driven 
sampling. Biological and behavioural data from 4901 
MSM were collected. Only behavioural data of HIV- 
negative individuals were considered. Three widely used 
risk indices to assess HIV acquisition risk among MSM 
were used to estimate individual HIV risk scores and PrEP 
eligibility criteria.
Results 4219 HIV- negative MSM were considered. 
Regardless the HIV risk score used and the city, 
percentages of MSM eligible for PrEP were found to 
range between 5.19% and 73.84%. Overall, the MSM 
Risk Index and the Menza score yielded broadly similar 
percentages, whereas the SDET Index provided estimates 
constantly lower across all cities. Although all the three 
scores correlated positively (r>0.6), their concordance 
was highly variable (0.01<CCC<0.62).
Conclusion Our findings showed the impact of 
different scoring systems on the estimation of the 
percentage of MSM who may benefit from PrEP in 
European cities. Although our primary aim was not to 
compare the performance of different HIV risk scores, 
data show that a considerable percentage of MSM in 
each city should be offered PrEP in order to reduce 
HIV infections. As PrEP is highly effective at preventing 
HIV among MSM, our findings provide useful, practical 
guidance for stakeholders in implementing PrEP at city 
level to tackle HIV infections in Europe.
INTRODUCTION
HIV transmission remains a challenging public 
health issue globally, despite intensive efforts to 
prevent new infections through health promotion 
and timely diagnosis and treatment. Preventive 
strategies and actions developed and delivered 
worldwide over the last 30 years among key popu-
lations have had a considerable impact on the 
epidemic. However, such a trend has not neces-
sarily been seen among men who have sex with 
men (MSM), where infections have continued to 
increase accounting for 38% of all new HIV diag-
noses in Europe in 2018.1
During the last decade, the use of antiretroviral 
treatment as prevention has been advocated for 
MSM at high risk of HIV infection.2 Pre- exposure 
prophylaxis (PrEP) is a biomedical preventive 
strategy that HIV- negative individuals can take 
prior to sexual contact to reduce their risk of HIV 
acquisition per single sexual act. Data indicate that 
PrEP is highly effective among MSM in reducing 
HIV incidence.2 3 In 2012, the US Food and Drug 
Administration approved the use of PrEP as a 
regimen to prevent HIV infection among people at 
risk. Similarly in Europe, recent studies have shown 
both the efficacy and cost- benefit of PrEP.2 4–7 
Consequently, the European Centre for Disease 
Prevention and Control, WHO, the European 
AIDS Clinical Society and the European Medicines 
Agency have recommended the use of PrEP among 
MSM as part of national comprehensive HIV and 
other STIs prevention programmes.8–10
However the evidence, PrEP availability within 
the European Union (EU) continues to be limited. 
Indeed, recent studies suggest that almost 500 000 
MSM are not able to access PrEP despite their 
desire to use it.11 This situation is partly due to 
different European Member States (MS) being at 
very different stages of policy and implementa-
tion. For instance, while some countries remain 
in the early stages of developing national guide-
lines for the implementation of PrEP, others are 
much more advanced and have already started to 
deliver it routinely as a part of their national HIV/
STI prevention strategies. In particular, among 
the 13 cities where our Sialon II study was imple-
mented, all but 4 cities (Bratislava, Bucharest, Sofia, 
Vilnius) currently have PrEP programmes avail-
able at the national level. Unsurprisingly perhaps, 
one of the main challenges in implementing PrEP 
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is the allocation of adequate funding and the estimation of the 
percentage of potential PrEP users who may wish to access it. 
Early estimates regarding PrEP need have relied mainly on end- 
user intentions or expressions of willingness to use it. However, 
HIV self- perceived and clinically assessed risk may not neces-
sarily converge; resulting in people at high risk of HIV acquisi-
tion not receiving PrEP. Therefore, the possibility of estimating 
the percentage of eligible PrEP users among MSM is an impor-
tant step to ensure national prevention strategies are feasible and 
effective.
Over the years, a number of indices have been developed 
and validated (mainly in the USA) to assess an individual’s 
risk and identify MSM that could potentially be offered PrEP. 
The most widely accepted scoring systems include the 4- item 
Menza score,12 the 7- item HIV Incidence Risk Index for MSM 
(HIRI- MSM)13 and the 4- item San Diego Early Test (SDET) 
score.14
To our knowledge, these indices have never been used to esti-
mate the percentage of potential PrEP users at community level. 
Using data from a European bio- behavioural survey (Sialon II) 
carried out in 13 cities among MSM populations and applying 
the above- mentioned HIV risk scoring systems, this current 
paper estimates and compares the percentage of MSM poten-
tially eligible for PrEP at city level. The main objective of this 
paper therefore is to estimate the number of MSM who may 
benefit in each city of using PrEP independently from their risk 
self- assessment or request.
MATERIALS AND METHODS
A detailed description of the Sialon II methodology has been 
published elsewhere.15 Here, we present the main methodolog-
ical aspects related to this secondary analysis.
Study design and setting
Sialon II was a multicentre bio- behavioural survey with the 
concomitant collection of biological (oral fluid (OF) or blood 
specimens) and behavioural data. The survey was implemented 
in 13 European cities during April 2013 to November 2014 
using a dual- frame sampling strategy. Time- location sampling 
(TLS) or respondent- driven sampling (RDS) was used based on 
formative research. TLS was used in nine cities: Brussels, Sofia, 
Hamburg, Warsaw, Lisbon, Ljubljana, Barcelona, Stockholm and 
Brighton. RDS was used in four cities: Verona, Vilnius, Bucha-
rest and Bratislava.
Sample size
Sample size estimates were calculated based on the former Sialon 
I project and other available studies.16 Assumed HIV prevalence 
in the target population of 15%, a precision of 5%, a signifi-
cance level of 95% and a design effect of 2.0 provided a random 
clustered sample size of n=392 per study site. Accounting for 
possible invalid samples, a final target sample per city of n=408 
(TLS) and n=400 (RDS) was planned.
Data sources and measurements
Behavioural data, sociodemographic characteristics, sexual 
and testing behaviour and HIV status were collected through a 
self- completion questionnaire (note: the questionnaire was not 
designed specifically to collect information relating to PrEP). To 
allow for sampling weight calculations, items were included on 
venues attendance (TLS) and network size (RDS). All partici-
pants irrespective of the sampling method were asked to provide 
a biological specimen (OF or blood).
Participants
Men were included if they had any kind of sex with another 
man during the 12 months before enrolment, provided written 
informed consent and agreed to donate an OF or blood spec-
imen (TLS and RDS, respectively). Men younger than 18 years 
were excluded. For this analysis, participants with an OF/serum 
positive HIV test result were excluded to ensure estimates are 
based on actual potentially eligible PrEP users (ie, MSM who are 
HIV negative).
Calculation of HIV risk scores
Outcome variables were three indices to identify MSM at risk of 
acquiring HIV: a revised CDC version of the HIRI- MSM called 
the MSM Risk Index,13 17 the Menza score12 and the Amsterdam 
version of the SDET score.14 18 Individual scores were calcu-
lated on the basis of the items of the Sialon II questionnaire. 
Some minor adjustments for generating the HIV risk scores were 
needed as our questions differed slightly from the items used in 
the original indices (table 1). All changes were conservative; in 
other words, the estimates presented in this paper are likely to 
underestimate the percentage of MSM eligible for PrEP.
Statistical analysis
Following the calculation of risk scores, analysis was carried 
out separately for all 13 participating cities. To calculate the 
sampling weights, a procedure was devised based on previous 
publications and methodological guidelines.15 19 20 All point esti-
mates are reported with their respective sample size, 95% CIs 
and estimated design effect (DE). In order to assess the concor-
dance between the percentage of PrEP eligible users based on the 
three HIV risk scores, Lin’s concordance correlation coefficient 
(CCC) and Bland- Altman limits of agreement were used.21 22 
Pearson’s r correlation was used to estimate the linearity of the 
estimates.
RESULTS
This analysis is based on 4219 HIV- negative MSM recruited 
across 13 European cities as part of the Sialon II study (TLS 
n=3010; RDS n=1209). A general description of the overall 
sample is available in the Sialon II core publications.23 24 Our esti-
mates based on three HIV risk acquisition scores are presented in 
table 2 and figure 1, organised by city to illustrate how the risk 
scores perform across cities.
Overall, our estimates of potentially eligible PrEP users are 
broadly similar for both the MSM Risk Index and the Menza 
score, although the SDET Index produces consistently lower 
estimates across all cities, compared with the other two. City 
comparisons show that Sofia is the city with the highest esti-
mates of eligible PrEP users regardless of the risk index (64.69%, 
73.84% and 23.57% for MSM Risk Index, Menza and SDET 
scores, respectively). In contrast, Bucharest, Verona and Vilnius 
show the lowest percentages, although not uniformly on all 
scores. The MSM Risk Index and Menza scores produce very 
similar estimates of eligible PrEP users in Bratislava, Bucharest 
and Vilnius, whereas Ljubljana is the only city where the esti-
mates obtained using the Menza is lower than that using the 
MSM Risk Index (33.62% vs 46.28%). As far as the SDET Index 
is concerned, Ljubljana shows a potential PrEP user estimate far 
higher than other cities with comparable estimates obtained 
using Menza and the MSM Risk indices. Hamburg shows a 
considerable percentage of potential PrEP users when SDET and 
Menza indices are used, whereas the MSM Risk score estimate 
is much lower.
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The CCC between the MSM Risk score and the Menza score 
is 0.62 (95% CI 0.31 to 0.92; r=0.73). The same coefficient 
between the Menza score and the SDET score yields 0.09 (95% 
CI 0.00 to 0.19; r=0.65), while between the MSM Risk score and 
the SDET score the CCC is 0.11 (95% CI 0.01 to 0.22; r=0.728). 
Figure 2 shows the concordance correlation graph and the limits 
of agreement plot comparing the different estimates based on 
the three HIV risk scores. Figure 2(A1) presents the agreement 
between the MSM Risk score and the Menza score. The latter 
seems to overestimate the percentage of potential PrEP users with 
the exception of few cities (Ljubljana, Vilnius and Verona). The 
Bland- Altman limits of agreement (figure 2(A2)) confirms the 
overall overestimate with all estimates laying within the 95% CI 
and Ljubljana right on the upper limit. Figure 2(B1) shows the 
agreement between the MSM Risk score and the SDET score. 
Compared with the SDET, the MSM Risk score overestimates 
the percentage of potential PrEP users for all cities. Although 
the Bland- Altman’s limits of agreement (figure 2(B2)) confirms 
this finding, all estimates but Sofia lay within the 95% CI with 
Hamburg on the lower limit. The comparison of SDET score 
versus the Menza score (figure 2(C1)) shows the overestimated 
percentages of MSM eligible for PrEP. In this case as well, Sofia 
lays outside the 95% CI (figure 2(C2)).
DISCUSSION
Previous attempts to estimate the need for PrEP have often 
relied solely on end- user intentions to use PrEP. A recent paper 
reported that 17.4% or 500 000 MSM (95% CI 420 000 to 
610 000) in EU countries who would be ‘very likely’ to use PrEP 
if they could access it.11 This estimate is based on a self- reported 
intention that could potentially be determined by an individual’s 
perception of their own risk of HIV acquisitions and/or their 
perception(s) of the benefit of using PrEP.
Recently, a Canadian study among MSM found that 48.3% 
HIV- negative participants who perceived themselves as at low 
risk, met a behaviourally based criterion for PrEP prescription.25 
In Thailand, another study found even larger discrepancies.26 
A Belgian study also showed that self- reported risk perception 
was not a good indicator for PrEP eligibility.27 This suggests 
that simply using self- perceived HIV risk as an indicator of 
PrEP eligibility can lead to widely varying estimates of potential 
PrEP beneficiaries. The consequences of such variation relate to 
potentially continued and/or increased HIV transmission, and 
may add to cost- effectiveness of public health expenditure, that 
is, allocating resources to implement PrEP at country level by not 
accurately targeting those most in need.




















Barcelona 338 36.73 28.25 to 45.21 4.24 52.83 44.94 to 60.72 3.42 10.82 8.41 to 13.22 0.82
Bratislava† 380 46.20 39.14 to 53.14 2.12 49.00 42.09 to 55.87 2.04 21.2 15.50 to 26.98 2.12
Brighton 334 37.89 31.49 to 44.30 1.14 51.91 41.13 to 62.70 3.04 17.14 12.84 to 21.44 0.85
Brussels 332 41.07 33.20 to 48.95 3.71 53.91 44.97 to 62.84 4.65 18.88 13.80 to 23.95 2.43
Bucharest† 147 30.00 19.96 to 40.06 1.84 29.1 19.68 to 38.51 1.65 5.19 1.82 to 8.55 0.89
Hamburg 340 31.25 23.74 to 38.75 2.56 49.14 39.05 to 59.23 3.99 21.22 15.43 to 27.01 1.96
Lisbon 302 30.42 23.39 to 37.44 1.89 40.51 31.31 to 49.70 2.85 12.12 5.22 to 19.03 3.63
Ljubljana 331 46.28 39.68 to 52.87 2.59 33.62 23.50 to 43.75 6.80 21.05 16.30 to 25.79 2.01
Sofia 344 64.69 58.31 to 71.06 0.36 73.84 68.20 to 79.48 0.33 23.57 15.80 to 31.34 0.68
Stockholm 338 31.60 25.87 to 37.33 1.09 36.98 30.27 to 43.68 1.38 13.31 7.21 to 19.42 2.32
Verona† 368 33.7 27.36 to 39.96 1.77 26.9 20.14 to 33.68 2.34 9.96 5.84 to 14.04 1.88
Vilnius† 314 29.4 23.07 to 35.70 1.66 26.6 20.59 to 32.57 1.59 9.52 5.84 to 13.11 1.32
Warsaw 351 39.35 33.84 to 44.83 0.74 47.38 37.95 to 56.81 2.08 13.75 8.44 to 19.05 1.38
*Participants with HIV- positive laboratory test results were excluded.
†Indicates RDS sampling.
HIRI- MSM, HIV Incidence Risk Index for MSM; MSM, men who have sex with men; RDS, respondent- driven sampling; SDET, San Diego Early Test.
Figure 1 HIV risk scores among European men who have sex with men (MSM) enrolled in the Sialon II study (participants with positive HIV 
laboratory test results were excluded). CDC, Centre for Disease Prevention and Control.
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In order to reduce self- perception bias, in this paper we esti-
mated the percentage of potential PrEP users on a population 
level, using a set of validated indices that are commonly used 
by clinicians to assess PrEP indication at individual level. Our 
data show the minimum percentages of MSM population, in 
each city, that should be offered PrEP to have an impact on HIV 
epidemic. These percentages represent the lower level of PrEP 
implementation at city- level, as WHO recommends access to 
PrEP for anyone who belongs to an high HIV incidence popula-
tion, regardless of the use of HIV risk scoring systems.
Both the MSM Risk Index and the Menza scores identify large 
percentages of MSM who could be eligible for PrEP use, and 
even the SDET, with much lower estimates overall, identifies a 
significant percentage of MSM who met the criteria for PrEP 
prescription in all cities. Importantly, our estimates are higher 
than the percentage of HIV- negative MSM who reported to have 
ever taken PrEP in a survey carried out 4 years after Sialon II was 
conducted (European- MSM- Internet- Survey 2017).28 In addi-
tion, PrEP eligibility, as assessed using HIV risk scores, refers 
to a past risk. It has to be considered that MSM who may have 
not taken risk so far and, therefore, are not eligible for PrEP 
yet, would anyway benefit from PrEP use in terms of likelihood 
in engaging in HIV high- risk behaviours in the coming months. 
The objective estimates of MSM eligible for PrEP as provided in 
this paper, along with the larger percentage of MSM who may 
benefit from PrEP use and the recently described disparities in 
MSM’s PrEP uptake,29 indicates that, despite the concerted PrEP 
promotion efforts of civil society and public health organisations 
across EU member states, a large gap in PrEP access exists.11
The variation of the estimates by the three different indices 
in our analysis most likely reflects the different factors and the 
scoring algorithms used in their calculation. The CDC version 
of MSM Risk Index and the Menza score provided broadly 
similar ranges of percentages of MSM potentially eligible for 
PrEP compared with SDET. Both the similarity between MSM 
Risk Index and Menza score and their difference with the SDET 
are reflected in the size of concordance coefficients: the SDET 
Index performs very differently compared with the other two. 
These results are consistent with the different ways in which 
the scores have been developed and validated. In fact, the CDC 
version of MSM Risk Index and the Menza score are based on 
a common approach in terms of variables to be considered in 
the algorithm and reflect the validation samples. The character-
istics of the MSM cohorts used to validate the scores, particu-
larly related to age and drug use, may have had a significant 
impact. Only the MSM Risk Index considers age, inversely with 
scores increasing for younger adults. Neither Menza nor SDET 
consider age in their calculation algorithm. Thus, the MSM Risk 
Index will lead to higher estimates in cities with younger MSM 
populations. This is reflected in our data: in cities with <10% 
of Sialon II participants being older than 44 years (Bratislava, 
Bucharest, Ljubljana, Sofia and Warsaw23), our estimates are 
higher compared with cities with older participants (Barcelona, 
Hamburg, Lisbon).23 For the Menza score drug use is central, 
with the weight originally assigned being larger than the sum 
all other items. Thus, in Bratislava, Hamburg, Sofia, Stockholm, 
Vilnius and Warsaw with use of poppers being more frequent,30 
estimates of those potentially benefiting from PrEP are higher. 
The SDET, again, takes a different approach, only considering 
sexual behaviour and previous bacterial infections. Given the 
well- established associations between the use of recreational 
drugs and HIV infection risk within MSM populations30 and the 
possibility that sexual risk behaviours considered by the score 
do not capture all aspects, the SDET estimates of MSM eligible 
for PrEP use may be underestimated. Therefore, in cities with 
larger percentages of MSM diagnosed with bacterial STI(s) in 
the previous year (Brussels, Bucharest, Hamburg, Sofia), a larger 
percentage of MSM would be identified as potentially benefiting 
from PrEP. Of all cities, the estimates for Sofia are highest regard-
less of the risk index considered. We suggest that this is due to 
Concordance Correlation Coefficient 
A1) MSM Risk score vs Menza score B1) MSM Risk score vs SDET score C1) Menza score vs SDET 
    
Bland-Altman limits of agreement 
A2) MSM Risk score vs Menza score B2) MSM Risk score vs Menza score C2) Menza score vs SDET 
   
 
 
Figure 2 Estimates of men who have sex with men (MSM) potentially eligible for pre- exposure prophylaxis (PrEP) and their concordance correlation 
coefficient and Bland- Altman limits of agreement.
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the young age, extensive popper use and the frequent diagnosis 
of at least one bacterial STI in the previous year, resulting in high 
estimates for all three risk scores.
Our data show clearly that the choice of risk index has impor-
tant implications for all stakeholders involved including policy 
makers, public health services and PrEP users themselves. Given 
the different risk score algorithms, different estimates are to 
be expected which implies that the direct comparisons of the 
percentage of eligible PrEP users are only meaningful when 
considering the characteristics of the populations and items used 
in the scoring systems. In addition, these scores have been devel-
oped for clinical purposes, primarily on a data- driven approach 
and without theoretical underpinnings from behavioural and 
social sciences. This means that they may reflect the specific 
sociocultural and historical context in which these indices were 
developed (US cohorts with mostly white non- Hispanic MSM). 
Future European studies addressing these wider issues of theo-
retical underpinning and validation are important issues not only 
for the European context.
In terms of the limitations of our analysis, it is important to 
note that the sampling methodology on which Sialon II was 
based (TLS and RDS) can result in quite different sample char-
acteristics which may persist even after applying weighting 
corrections.15 In most Western European cities, the percentage 
of young MSM aged ≤25 years in the samples is smaller than 
in the central/eastern European cities. This could impact on the 
estimates of the scores, particularly when age is considered as in 
the MSM Risk Index. Another important limitation is that, at 
the time of the Sialon II survey (2013–14) PrEP was neither well 
known nor available outside of studies and trials, therefore the 
Sialon II questionnaire was not designed specifically to collect 
data necessary to calculate precisely the three indices used in this 
current article.
In order to estimate the various risk scores, some minor adap-
tations were required (table 1). These adaptations however, were 
made relatively conservatively so it is arguably likely that the 
percentage of eligible PrEP users is underestimated for all scores. 
Nevertheless, caution should be used when extending our find-
ings to MSM of different cities and social contexts, as the survey 
was based on 13 European cities and contextual factors not 
measured in the survey might have had an impact on the data 
and related estimates.
Answering the question which risk index is more valid and 
whether asking directly to the individuals about their self- 
perceived risk leads to more accurate estimates, would require 
longitudinal validation studies. Independent of the index, 
health services and policy makers need to be mindful of local 
demographics (above all age) and behavioural (above all drug 
use) patterns among MSM if choosing one of the three indi-
cators discussed here to assess eligibility for PrEP. The pattern 
of results confirms that roll- out of PrEP should be considered 
widely, however, this study also shows that adopting different 
approaches to risk assessment will lead to significantly different 
estimates of potential PrEP beneficiaries. Considering this, the 
possibility of combining the estimates provided by the three HIV 
risk indices according to the specific city/region demography and 
behaviours should be considered carefully.
A significant percentage of European MSM should be offered 
PrEP and even considering only the lowest estimates obtained in 
our study, the allocation of funding for PrEP should be increased 
significantly to meet the needs of this vulnerable population. 
The available evidence about PrEP efficacy, safety and scalability 
is now overwhelming. It is now a matter of political willing-
ness, although many factors may play a role, to allocate sufficient 
funding to reduce the burden of HIV among MSM.
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Key messages
 ► Pre- exposure prophylaxis (PrEP) is highly effective at 
preventing HIV among MSM; however, there is still 
uncertainty on how best to identify those to whom PrEP 
provision should be prioritised.
 ► The three most widely used HIV risk indices in the 
MSM population yielded different estimates with poor 
concordance, particularly when the San Diego Early Test score 
is considered.
 ► Regardless of the HIV risk index used, a considerable 
percentage of European MSM, higher than that have had 
access so far, should be offered PrEP in order to reduce new 
HIV infections.
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